Ombitasvir
CAS: 1258226-87-7
Ref. 3D-AO178040
25mg | 136,00 € | ||
50mg | 180,00 € | ||
100mg | 260,00 € | ||
250mg | 406,00 € | ||
500mg | 542,00 € |
Produktinformation
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<span class="text-smallcaps">L</smallcap>-valyl-<smallcap>L</span>-prolinamide]
- <span class="text-smallcaps">L</smallcap>-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-<smallcap>L</span>-valyl-
- L-Prolinamide, 2,2′-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- ABT 267
- 2,2′-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide]
Ombitasvir is a potent inducer of the cytochrome P450 enzyme system. It has been shown to inhibit the growth of infectious diseases by binding to α7 nicotinic acetylcholine receptors, which are located on cells in the liver, brain, and other organs. Ombitasvir has also been shown to be a potent inhibitor of antiviral resistance by binding to the viral envelope protein. This drug is used as an oral treatment for chronic hepatitis C infections with or without HIV co-infection in adults. It is also used in combination with other antiviral drugs for the treatment of chronic HBV infection in adults.
Chemische Eigenschaften
Technische Anfrage zu: 3D-AO178040 Ombitasvir
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.